Azatadine

In today's world, Azatadine represents a very important issue that impacts people's daily lives. Since its emergence, Azatadine has generated controversy and debate, arousing widespread interest in society. Over the years, Azatadine has evolved and become a topic of study and research that covers various areas, from science and technology to politics and culture. In this article, we will explore in depth the importance and impact of Azatadine in today's society, analyzing its influence on different aspects of daily life and offering a comprehensive view of this phenomenon that continues to generate interest and attention around the world.

Azatadine
Clinical data
Trade namesOptimine
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
  • 11-(1-Methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzocycloheptapyridine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22N2
Molar mass290.410 g·mol−1
3D model (JSmol)
  • n4c3\C(=C1/CCN(C)CC1)c2ccccc2CCc3ccc4
  • InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3 checkY
  • Key:SEBMTIQKRHYNIT-UHFFFAOYSA-N checkY
  (verify)

Azatadine (Optimine) is a first-generation antihistamine and anticholinergic drug that was synthesized in 1963 by Schering-Plough, a former American pharmaceutical company.[1][2]

It was patented in 1967.[3] It has been succeeded by both loratadine and desloratadine.[4]: 53  and marketing approvals have been widely withdrawn.[5][6][7][8]: 290 [9]

See also

References

  1. ^ Katelaris C (December 1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–7. PMID 1982614.
  2. ^ Small P, Barrett D, Biskin N (February 1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–31. PMID 1968324.
  3. ^ US 3326924, Villani FJ, Caldwell W, "Azatadine", issued 1967 
  4. ^ Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Vol. 5. Springer Science & Business Media. ISBN 9784431993629.
  5. ^ "Azatadine". Drugs.com.
  6. ^ Food and Drug Administration (2005). "Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications". Federal Register 70 FR 10651.
  7. ^ Food and Drug Administration (2007). "Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions". Federal Register 72 FR 8184.
  8. ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.
  9. ^ "OGD Suitability Tracking Report (Sorted by Drug Name)". FDA.